“I don’t think that we’re out of the woods and I do think that the biggest threat with regard to this sort of stuff is less the tariffs than the feeling of uncertainty for investors as to what comes next. And that’s where the pharmaceutical EO starts to come in or the negotiations over the tax bill. What actually makes …
Read More »